Parthenolide inhibits Hsp90α ATPase activity and overcomes acquired BRAF-inhibitor resistance in cutaneous melanoma
Phytomedicine · 2025
DOI: 10.1016/j.phymed.2025.157151 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2025. Verfasst von Xiao-Qi Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Consun Chinese Medicines Research Centre for Renal Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China; Research…. Hauptthemen laut MEDLINE: Sesquiterpenes, Melanoma, Proto-Oncogene Proteins B-raf, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: General Research Fund of Shanghai Normal University, University Grants Committee Research Grants Council, National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Oncogenic mutations in the BRAF gene, particularly the V600E mutation, are present in roughly half of metastatic cutaneous melanoma cases. BRAF inhibitors (BRAFi) have shown significant clinical efficacy; however, their long-term effectiveness is frequently limited by the development of resistance. Parthenolide, a sesquiterpene lactone derived from medicinal herbs, has previously been reported to exhibit anti-melanoma effects and to disrupt signaling pathways associated with BRAFi resistance. PURPOSE: This study aimed to evaluate the potential of parthenolide to overcome resistance to BRAFi in melanoma. STUDY DESIGN AND METHODS: The effects of parthenolide on BRAFi-resistant melanoma cells were assessed using cell viability, apoptosis, and cell cycle assays. In vivo efficacy and safety were evaluated in a BRAFi-resistant melanoma xenograft mouse model. Target identification and validation were performed using network pharmacology, molecular docking, surface plasmon resonance, and Western blotting. RESULTS: Parthenolide inhibited cell viability and induced apoptosis and S-phase cell cycle arrest in BRAFi-resistant melanoma cells. In vivo, parthenolide significantly suppressed tumor growth and reduced tumor weight in BRAFi-resistant melanoma xenografts without apparent toxicity. Mechanistically, parthenolide stably interacted with the N-terminal ATPase domain of Hsp90α and dose-dependently inhibited its ATPase activity. Hsp90α functions as a chaperone for several oncoproteins involved in signaling pathways driving BRAFi resistance. Parthenolide reduced the levels of several Hsp90α client proteins and inhibited their downstream pathways, including PI3K/Akt, Ras/Raf/MEK, and Src/STAT3, in BRAFi-resistant melanoma cells. Moreover, the Hsp90 activator tamoxifen attenuated the effects of parthenolide in these cells. CONCLUSION: Our findings provide the first evidence that parthenolide can overcome BRAFi resistance in melanoma, highlighting its potential as a lead compound for the development of Hsp90α inhibitors to manage BRAFi-resistant cutaneous melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Consun Chinese Medicines Research Centre for Renal Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China; Research and Development Centre for Natural Health Products, HKBU Shenzhen Res…
- Department of Traditional Chinese Medicine, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
- Department of Pathology, Tseung Kwan O Hospital, Tseung Kwan O, Hong Kong SAR, China.
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- Department of Nutrition, Georgia State University, Atlanta, GA 30303, USA.
Förderung
- General Research Fund of Shanghai Normal University
- University Grants Committee Research Grants Council
- National Natural Science Foundation of China
- Shenzhen Science and Technology Innovation Committee
Zitieren
APA
Wang, X. Q., Yu, X. F., Li, A. S., Han, R. X., Wang, L., Wu, J. Y., Wu, Y., He, J. J., Liu, B., Tsui, W. M., Lu, G. H., Mo, H., Fu, X. Q., & Yu, Z. L. (2025). Parthenolide inhibits Hsp90α ATPase activity and overcomes acquired BRAF-inhibitor resistance in cutaneous melanoma. Phytomedicine. https://doi.org/10.1016/j.phymed.2025.157151
Vancouver
Wang XQ, Yu XF, Li AS, Han RX, Wang L, Wu JY, et al. Parthenolide inhibits Hsp90α ATPase activity and overcomes acquired BRAF-inhibitor resistance in cutaneous melanoma. Phytomedicine. 2025. doi:10.1016/j.phymed.2025.157151
BibTeX
@article{Wang2025,
author = {Wang, Xiao-Qi and Yu, Xiao-Fei and Li, Amy Sze-Man and Han, Rui-Xuan and Wang, Li and Wu, Jia-Ying and Wu, Ying and He, Jin-Jin and Liu, Bin and Tsui, Wilson Man-Shan and Lu, Guang-Hua and Mo, Huanbiao and Fu, Xiu-Qiong and Yu, Zhi-Ling},
title = {Parthenolide inhibits Hsp90α ATPase activity and overcomes acquired BRAF-inhibitor resistance in cutaneous melanoma},
journal = {Phytomedicine},
year = {2025},
doi = {10.1016/j.phymed.2025.157151}
}
EUVIMED